ProMIS Neurosciences to Participate in Major Conference
ProMIS Neurosciences Inc. (Nasdaq: PMN), a prominent player in the biotechnology sector, is gearing up for the H.C. Wainwright 26th Annual Global Investment Conference. This significant event is just around the corner, where Neil Warma, the company’s Chief Executive Officer, will present exciting developments in therapies aimed at neurodegenerative diseases.
Exploring Therapeutics Development
During the conference, Mr. Warma will provide a comprehensive overview of the company’s cutting-edge antibody therapeutics. These innovative treatments are specifically engineered to target toxic misfolded proteins that are often linked to conditions such as Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). In addition, he will participate in one-on-one meetings to engage with potential investors and stakeholders.
How to Access the Conference Presentation
The company’s presentation will be available for on-demand viewing starting September 9, 2024, at 7:00 a.m. Eastern Time. You can access it through ProMIS Neurosciences' events page. After the live presentation, a replay will be offered for 30 days, allowing ample time for review.
About ProMIS Neurosciences and Its Contributions
ProMIS Neurosciences is more than just a clinical stage biotechnology company; it is at the leading edge of developing targeted therapeutic solutions that address protein mismanagement in neurodegenerative diseases. The firm utilizes its proprietary platform, ProMIS™, which employs advanced computational techniques to identify and predict targets associated with these diseases.
Innovations in Disease-Specific Therapeutics
By concentrating on Disease-Specific Epitopes found on misfolded proteins, ProMIS is revolutionizing the treatment approach for challenging conditions like Alzheimer’s, ALS, and MSA. The innovative strategies employed by the company represent a new standard in the development of effective therapies, highlighting potential breakthroughs that could significantly enhance patient outcomes.
Engagement and Further Information
If you are interested in learning more about ProMIS Neurosciences, the company encourages you to visit their official website. ProMIS is dedicated to transparency and engagement, welcoming media inquiries and investment discussions to explore the promising future of their therapeutic innovations.
Contact Information
For media inquiries, please contact info@promisneurosciences.com. For investor relations, reach out to Anne Marie Fields, Managing Director at Precision AQ, via annemarie.fields@precisionaq.com or call 212-362-1200.
Frequently Asked Questions
What is the focus of ProMIS Neurosciences?
ProMIS Neurosciences primarily focuses on developing antibody therapeutics that target toxic misfolded proteins involved in neurodegenerative diseases.
Who is presenting at the conference?
Neil Warma, the CEO of ProMIS Neurosciences, will be the presenter at the H.C. Wainwright conference.
When will the presentation be available for viewing?
The presentation will be available on demand starting September 9, 2024, on the company's website.
What diseases are targeted by ProMIS's therapeutics?
The therapeutics developed by ProMIS focus on diseases such as Alzheimer’s, ALS, and MSA.
How can investors contact ProMIS Neurosciences?
Investors can contact Anne Marie Fields at Precision AQ for inquiries related to investor relations.
